Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults
Inclusion Criteria:
- Acute lymphoblastic leukemia of the mature B-cell type (L3-ALL)
- High-grade non-Hodgkin's lymphoma of the following subtypes (WHO classification)
- Burkitt's lymphoma (including atypical Burkitt's lymphoma)
- Precursor B-lymphoblastic lymphoma
- Anaplastic large-cell lymphoma (Ki1+, B-, T- oder Null-cell-type)
- Mediastinal large B-cell-lymphoma (subtype of diffuse large B-cell lymphoma)
- Age = 18 years
- Patient's Informed Consent
Exclusion Criteria:
- Serious complications caused by leukemia/ lymphoma or by a second illness: e.g.
- Severe, unmanageable complications such as sepsis, pneumonia with oxygen
deficiency,
- Shock, hemorrhage at the time of diagnosis
- Renal insufficiency from leukemia/lymphoma-unrelated causes
- Severe cardiac or hepatic insufficiency
- Severe obstructive or restrictive lung disease that would compromise patient's
treatment with intensified chemotherapy
- HIV infection
- Secondary lymphoma following prior chemotherapy/ radiotherapy or an active
second malignancy
- Known severe allergy to foreign proteins
- Cytostatic pretreatment for B-ALL/lymphoma (exceptions: short-term administration of
steroids = 7 days, single administration of vincristine or cyclophosphamide, one
cycle of CHOP, a single administration in an emergency of other cytostatic agents)
for another malignant disease within the last 5 years
- Pregnancy/ nursing period
- Severe psychiatric illness or other circumstances giving ground to the assumption
that a patient cannot give his consent to therapy or act co-operatively
- Absence of patient's informed consent
- Participation in another clinical study that would possibly interfere with study
therapy